Celgene Continues Active January With $9B Juno Acquisition
Celgene has agreed to buy rival biotechnology business Juno Therapeutics for around $9 billion, the companies said Monday, marking the second multibillion-dollar acquisition made by Celgene this month....To view the full article, register now.
Already a subscriber? Click here to view full article